• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    More On GLENMARK.NS

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Glenmark Pharmaceuticals Ltd. (GLENMARK.NS)

    -NSE
    829.45 Up 11.45(1.40%) Apr 29, 5:59AM EDT
    ProfileGet Profile for:
    Glenmark Pharmaceuticals Ltd.
    Glenmark House
    B D S Marg
    Mumbai, 400099
    India - Map
    Phone: 91 22 4018 9999
    Fax: 91 22 4018 9990
    Website: http://www.glenmarkpharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:11,500

    Business Summary 

    Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, Latin America, Europe, the United States, and internationally. The company provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system(CNS), dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It also offers Crofelemer, an anti-diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti-retro viral therapy. The company’s products under development include GRC 17536, which has completed Phase IIa of clinical trials for neuropathic pain and respiratory disorders; GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial; Vatelizumab (GBR 500) that is in Phase IIb study for multiple sclerosis; GBR 830, an anti-OX40 monoclonal antibody, that has completed Phase I clinical trials for autoimmune disorders; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 1302, a bispecific antibody, which has completed its preclinical trials for the treatment of breast and other cancers. The company was founded in 1977 and is headquartered in Mumbai, India.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Glenmark Pharmaceuticals Ltd.

    Key Executives 
     PayExercised
    Mr. Glenn Mario Saldanha , 46
    Chairman, Chief Exec. Officer, Managing Director, Member of Stakeholder's Relationship Committee and Member of Nomination & Remuneration Committee
    83.65MN/A
    Mr. Rajesh V. Desai , 58
    Chief Financial Officer, Exec. Director and Member of Corp. Social Responsibility Committee
    21.73MN/A
    Mr. Sanjay Kumar Chowdhary ,
    Compliance Officer and Company Sec.
    2.22MN/A
    Mrs. Cherylann Maria Pinto B.Pharm, 49
    Director of Corp. Affairs, Exec. Director, Chairman of Corp. Social Responsibility Committee and Member of Stakeholder's Relationship Committee
    25.64MN/A
    Dr. Michael Buschle , 56
    Chief Scientific Officer and Pres of Biologics Research
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in INR.